Ranking Profile - Akebia Therapeutics Inc

Introduction

Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company that carries out the development and commercialization of novel therapeutics based on hypoxia-inducible factors for patients with kidney disease and other metabolic disorders. Its lead product candidate vagadusta is a HIF-PH inhibitor, a regulator for the production of red blood cells, RBCs, in the body, as well as other important metabolic functions for the treatment of anemia due to chronic kidney disease (CKD). The company's product pipeline includes AKB-5169, an oral treatment for inflammatory bowel disease. Akebia Therapeutics works in partnership with Otsuka Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation and Vifor Pharma Management Ltd for the development and commercialization of its pipeline products. The company operates in the US and Ireland. Akebia Therapeutics is headquartered in Cambridge, Massachusetts, the US.